Abstract
Introduction
Schizophrenia (SCZ) is a disabling group of mental illnesses characterized by paranoia, hallucinations, delusions, poor planning, disorganized communication, blunted effect, and reduced motivation affecting about 1% of the world population. Although the etiology of SCZ is entirely unknown, there is much evidence Original research article DOI: 10.1515 DOI: 10. /rrlm-2017 that genetic factors play important roles in pathogenesis and the development of SCZ (1) (2) (3) (4) (5) .
Melatonin, also known as N-acetyl 1-5-methnxytryptamine, is a neuro hormone synthesized and secreted by the pineal gland of the mammalian brain to regulate the circadian rhythm, and affects other physiological functions with peaks during night time (6) . This hormone for beginning its performance must interact with receptors, MT1 (Mel 1a encoded by MTNR1A) and MT2 (Mel 1b , encoded by MTNR1B), which are two membrane receptors isoforms to transmit the action and effects of melatonin by G-protein coupled 7-transmembrane receptors mechanism. In addition, MT3 (Mel 1c ) cloned from Zebrafish, Xenops, and Chicken has high affinity binding site for melatonin; orphan receptor GPR50 is a mammalian orthologous of MT3; however, its biological function remains unknown in humans and does not bind to melatonin (7, 8) .
In previous studies, night time peak in melatonin was observed as slacken in SCZ patients compared with healthy individuals, and this continues after treatment with antipsychotic drugs (9, 10) . In another research on SCZ and melatonin in 2010, Afonso et al. (11) reported that SCZ was characterized by neuroendocrine disturbance with diminished melatonin secretion, thus, they proposed that cure for this disorder should consider the correlation of sleep disruptions and low melatonin secretion and sleep efficiency in SCZ patients with low sleep quality improved with melatonin. It is assumed that melatonin expression and signaling may play a role in the development and pathogenesis of SCZ as regards melatonin. Signaling effect is basically mediated through its specific receptors like MTN1B related to SCZ and sleep distribution. In the present study, the association of gene polymorphisms between SCZ and MTN1B in a sample of Iranian SCZ patients was investigated through an analysis of two single nucleotide polymorphisms (SNPs) of the melatonin receptor gene. 
Materials and Methods

Ninety
SNP selection and Genotyping
Two SNPs were selected from MTN1B in the Medline data (rs10830963(C/G) and rs3781637(T/C)); these SNPs were strongly associated with different diseases for which sleep disturbances and sleep problems are risk factors, such as coronary heart disease and type2 diabetes (13) (14) (15) (16) ; however, the association between these SNPs and SCZ had not been described in previous studies. Therefore, the aim of the present study was to investigate the relation between MTN1B polymorphisms, rs10830963(C/G) and rs3781637(T/C), and SCZ risk.
Genotyping of MTN1B rs10830963(C/G) variant was performed using Polymerase Chain Reaction-Amplification Refractory Mutation System (PCR-ARMS) and NESTED-PCR, and ARMS-PCR modified methods (combination) (Nested-ARMS-PCR) were used for MTN1B rs3781637(T/C) variant genotyping. In fact, these methods were modified because the location of MTN1B rs3781637 (T/C) variant is very challenging for ARMS-PCR. As an advantage, this method prevents production of non-specific products and protection of SNP position for the next step of the process. The list of the primers used is available in Table 2 .
rs10830963(C/G) polymorphism of MTN1B
To amplify the region of MTN1B gene in (20 μL volume), 1 μL template DNA (~80-100 ng/ μL), 1 μL of each primer (10 pmol/μL), 10 μL mastermix (Ampliqon Taq 2x mastermix, Denmark), and 7 μL DNase-free water were added at the following condition: an initial denaturation 96 °C for 6 min and following that 30 cycles with this condition: denaturation 96°C for 30 s, annealing 49°C for 30 s, extension 72°C for 29 s, and the final extension was 72°C for 6 min. The product Size of this SNP was 312bp verified on 1.5% Agarose gel staining Ethidium Bromide by Electrophoresis after the PCR product was observed under UV light.
rs3781637(T/C) Polymorphism MTN1B
Nested-ARMS-PCR method was set up for the evaluation of polymorphism between SCZ and 
Statistical analysis
The statistical package SPSS version 22 (SPSS Inc, Chicago, IL) was used for statistical analyses. Binary logistic regression test was used for determining odds ratio (OR) and 95% confidence intervals (95% CI) of each variant. Association and frequencies of haplotype with SCZ were analyzed using SNPStats online software. The Pearson's X 2 was used for comparison of the categorical data. P<0.05 was considered statistically significant. The HardyWeinberg equilibrium (HWE) was examined using χ2 for each SNP.
Results
HWE was estimated separately for SCZ and
HCs. The HC group in rs3781637 (T/C) and rs10830963 (C/G) polymorphisms were in HWE (P=0.916, χ2 = 0.01 and P=0.586, χ2 =0.23, respectively), while the SCZ group were not in HWE in both SNPs (P<0.05).
The genotype and allelic frequencies of MTN1B polymorphisms are listed in Table 3 . The results indicated that MTN1B rs10830963(C/G) variant increased the risk of SCZ in codominant (OR=2.78. 95%CI=1.25-6.25, P=0.012. GG vs. CC) and recessive (OR=3.85, 95%CI=1.89-8.33, P<0.0001, GG vs. CC+GG). In heritance models, the G allele increased the risk of SCZ (OR=1.66, 95%CI=1.09-2.51, P=0.021) compared with C allele. It was found that the genotype and allele frequencies of MTN1B rs3781637 (T/C) variant all codaminant, and allele status were not associated with the risk or protection of SCZ in the study population. In addition, the haplotype analyses indicated that the TG haplotype of rs3781637 (T/C) and rs10830963 (C/G) polymorphisms could increase the risk of SCZ (OR=1.49, 95%CI=1.02-2.17, P=0.039) ( Table 4) . Also, the CC haplotype of rs3781637 (T/C) and rs10830963 (C/G) polymorphisms were different between case and HC individuals (P=0.0001).
The association between clinical and demographic characteristics of SCZ patients with MTN1B rs10830963(C/G) polymorphism in the dominant model is shown in Table 5 . There is no significant difference between clinical and demographic characteristics of SCZ patients and this variant in the dominant model (P>0.05). There was no significant difference between the groups concerning gender and age (P=1.000, and P=0.809, respectively).
Discussion
The influences of melatonin as neuro hormone on sleep and circadian phase are mainly mediated by activation of its two especial receptors. Melatonin receptor 1 A (MT1) is encoded by MTN1A and melatonin receptor 1 B (MT2) is encoded by MTN1B (17) . Previous studies showed decrease of melatonin secretion in SCZ patients compared to HCs, moreover, SCZ patients usually have sleep disturbances (18); consequently, the effectiveness of MTN1B hormone might be involved in SCZ development. SCZ is a multifactorial disease with highly heritable mental disorder, and factors such as urbanity, migration, sex, season of birth, pregnancy, and birth complications are possibly involved in the pathogenesis of the disease (19) .
The present study investigated the potential impact of MTN1B gene polymorphisms on the susceptibility and clinical pathological features of SCZ in an Iranian population in the southeast of Iran. The findings proposed that MTN1B rs10830963 (C/G) variant significantly increased the risk of SCZ. The results did not support an association between rs3781637 (T/C) variant of MTN1B gene and SCZ risk although TG and CC haplotypes of rs3781637 (T/C) and rs10830963 (C/G) genes were associated with developing SCZ.
A stratified analysis was performed by clinical and demographic characteristics of SCZ patients, and the findings proposed that patients with rs10830963 (C/G) did not show difference regarding CG+GG vs. CC variants.
There was not any study regarding relationship between MTN1B (rs3781637(T/C) and rs10830963(C/G) variants and SCZ risk, so the current results could not be compared with similar studies; however, Hae Jeong Park et al. investigated the association of Korean SCZ patients and MTN1B rs4753426; they found that this SNP was not correlated with SCZ in the codominant, dominant, and recessive models (9) . Another study was done on the association between MTN1B and occurrence of delusions (a sign of SCZ) by A de Jonghe et al., showing that neither rs10830962 nor rs3781638 polymorphisms were associated with the occurrence of delusions (20) .
These two SNPs were investigated with various diseases such as systemic lupus erythematous (SLE) (21), breast cancer (22) , polycystic ovary especially (23), type II diabetes (24) , and gestational diabetes (6, 25) . Tanev investigated the impact of MTN1B rs1562444, rs10830962, and rs10830963 polymorphisms on SLE on 109 SLE females and 101 healthy women; they found that CC genotype of rs10830963 polymorphism significantly increased the risk of SLE when compared with CG and GG genotypes (21) . No significant association was reported between the CG genotype of rs10830963 variant and breast cancer in Egyptian women; however, the GG of this SNP was associated with the risk of breast cancer (22) .
In a meta-analysis performed by Qing Xia et al., a significant association was revealed between MTN1B rs10830963 polymorphism and increase risk of type 2 diabetes (T2D) compared with alleles (G Vs. C, P=0.01) and recessive genetic model (P=0.001); subgroup analyses showed that the allele (G Vs. C) of MTN1B rs10830906 variant was associated with the risk of T2D in East Asia but not in South Asia and Caucasus (24) .
The results of a case-control study on Han Chinese individuals indicated that rs3781637 was associated with T2D in additive model and recessive model as a risk concerning T2D (26) .
The deviation from HWE is not clear in the present study population; its probable reasons are: small sample size, emigration, immigration, or consanguineous marriages that are common in this region of Iran (Zahedan, southeast Iran).
The current study has several limitations. Firstly, based on the published and Medline data several MTN1B polymorphisms have been identified in humans, while we investigated only two polymorphisms. Secondly, we did not consider differences by specific schizophrenia subtypes. Thirdly, small sample size (although Zahedan-city has almost one million population, we found just 92 patient with SCZ in this oneyear period).
In conclusion, the present study was the first attempt to demonstrate the feasible association between MTN1B SNPs and probability of SCZ risk in Iranian population, taking the MTN1B rs3781637 (T/C) and rs10830963(C/G) variants into account; rs10830963(C/G) was associated with the risk of SCZ development. Further studies are necessary with larger sample size and different ethnic groups to confirm the results. 
